Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.
Target Price
The average target price of RZLT is 5.2 and suggests 68% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell